195 filings
Page 4 of 10
8-K
f10r6svog1cu9r go28y
21 Mar 22
Regulation FD Disclosure
7:06am
S-8
u2g8i4q5ehfioks9zd
24 Feb 22
Registration of securities for employees
7:26am
POS AM
9vzqu
24 Feb 22
Prospectus update (post-effective amendment)
7:20am
POSASR
m7famdj1bugs9vqp5s
24 Feb 22
Automatic shelf registration (post-effective amendment)
7:12am
8-K
6zoje
24 Feb 22
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
7:07am
8-K
luz4ftna 6wvl58ay
22 Feb 22
Regulation FD Disclosure
7:45am
8-K
1tdlau9o
27 Jan 22
Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1
4:14pm
8-K
qn37e3 9s9r1k9q5p
22 Nov 21
Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
7:40am
8-K
5iw vvfw3
4 Nov 21
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
7:14am
8-K
cd19yxg0a3g9med9tyf
5 Aug 21
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
7:16am
8-K
0dcq sg0815
6 Jul 21
Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstanding
7:14am
8-K
p6x44k5
27 May 21
If approved, teplizumab will be the first disease-modifying therapy in T1D
9:55pm
8-K
1iy4d3yszx
25 May 21
Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab
9:36am
8-K
drax6ax0bhg
14 May 21
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
bbuu27m3 jr
6 May 21
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
7:24am